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ABSTRACT
Introduction Junior doctors are responsible for a 
substantial number of prescribing errors, and final- year 
medical students lack sufficient prescribing knowledge 
and skills just before they graduate. Various national and 
international projects have been initiated to reform the 
teaching of clinical pharmacology and therapeutics (CP&T) 
during undergraduate medical training. However, there 
is as yet no list of commonly prescribed and available 
medicines that European doctors should be able to 
independently prescribe safely and effectively without 
direct supervision. Such a list could form the basis for 
a European Prescribing Exam and would harmonise 
European CP&T education. Therefore, the aim of this 
study is to reach consensus on a list of widely prescribed 
medicines, available in most European countries, that 
European junior doctors should be able to independently 
prescribe safely and effectively without direct supervision: 
the European List of Essential Medicines for Medical 
Education.
Methods and analysis This modified Delphi study will 
recruit European CP&T teachers (expert group). Two Delphi 
rounds will be carried out to enable a list to be drawn 
up of medicines that are available in ≥80% of European 
countries, which are considered standard prescribing 
practice, and which junior doctors should be able to 
prescribe safely and effectively without supervision.
Ethics and dissemination The study has been approved 
by the Medical Ethics Review Committee of VU University 
Medical Center (no. 2020.335) and by the Ethical Review 
Board of the Netherlands Association for Medical Education 
(approved project no. NVMO‐ERB 2020.4.8). The European 
List of Essential Medicines for Medical Education will be 
presented at national and international conferences and 
will be submitted to international peer- reviewed journals. It 
will also be used to develop and implement the European 
Prescribing Exam.
INTRODUCTION
Prescribing is a core task of junior doctors, 
who are responsible for most hospital 
prescriptions.1 2 With an ever- expanding 
therapeutic arsenal and an increasing 
number of patients with comorbidity 
and polypharmacy, safe and effective 
prescribing has become an increasingly 
complex task. International studies have 
shown that junior doctors are responsible 
for a substantial number of prescribing 
errors1 3 and that at the time of graduation, 
junior doctors not only feel insufficiently 
prepared to prescribe safely and effectively 
but also have insufficient knowledge and 
skills to perform this task.4–8
This has prompted various national 
and international projects to reform 
teaching in clinical pharmacology and 
therapeutics (CP&T) in the undergrad-
uate medical curriculum. For example, in 
the UK and the Netherlands a prescribing 
assessment has been introduced for final- 
year students, to ensure that they have 
acquired the necessary knowledge before 
graduation.9–11 Other European countries 
might benefit from a similar initiative. As 
many countries do not have the time and 
resources to implement an assessment at 
a national level, we initiated an Erasmus+ 
Strengths and limitations of this study
 ► To our knowledge, this will be the first study to reach 
consensus on a European List of Essential Medicines 
for Medical Education.
 ► The Delphi method is the most suitable method to 
reach consensus anonymously with a large group of 
experts working in different countries.
 ► The European List of Essential Medicines for Medical 
Education will help to harmonise clinical pharmacol-
ogy and therapeutics (CP&T) education in Europe.
 ► There is already strong collaboration between 
European Association for Clinical Pharmacology 
and Therapeutics and WHO Europe, and the mem-
bers are recognised experts in the field of CP&T 
education.
 ► Recruiting a sufficient number of participants from 
all European countries will be a challenge.
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project (2019‐1 ‐ NL01 ‐ KA203‐060492) to develop, 
test and implement a standardised prescribing assess-
ment on safe prescribing (including knowledge and 
skills) for undergraduate medical students studying 
at medical schools in the European Union (ie, Euro-
pean Prescribing Exam (EuroPE+)). See http://www. 
prescribingeducation. eu/ for more information.
The assessment will be based on the ‘essen-
tial diseases in prescribing’ derived from a Delphi 
consensus study held in 2018.12 However, there is 
no consensus list of medicines that European junior 
doctors should be able to independently prescribe 
safely and effectively without direct supervision. This 
list will form the basis of the European Prescribing 
Exam (especially the skills part), and together with 
country- specific adjustments to reform educational 
programmes in CP&T in all European countries. 
This will complement the wish of the European Asso-
ciation for Clinical Pharmacology and Therapeutics 
(EACPT) to harmonise European training in CP&T13 
and will be included in a future revision of the Guide 
to Good Prescribing of the WHO.14 Previous studies 
of such lists have been based on the opinions of indi-
viduals or small groups of experts or were specific to 
one country.15–18 Therefore, the aim of this study is to 
reach consensus on a list of medicines that are widely 
prescribed and available in Europe and which Euro-
pean junior doctors should be able to independently 
prescribe safely and effectively without direct supervi-
sion, that is, the European List of Essential Medicines 
for Medical Education.
METHODS AND ANALYSIS
A modified Delphi method will be used as it has been 
shown to be an effective and successful method for 
reaching consensus on content of a CP&T curric-
ulum.12 19–23 As the availability of medicines differs 
between European countries, it is not possible to 
develop an all- encompassing list, but one that can 
be considered as a basis for European CP&T educa-
tion. Subsequently, each country can adjust the list 
based on the availability of medicines in its country. 
The study will start in October 2020 and will comprise 
three phases: phase I—creating a drug list, selecting 
an European expert panel and developing a web- based 
questionnaire in Castor Electronic Data Capture; 
phase II—sending a questionnaire to appointed coor-
dinators and phase III—Delphi consensus.




On the basis of the WHO Model List of Essential Medi-
cines,24 guideline therapies for the ‘essential diseases 
in prescribing’ (see online supplemental appendix 
1), a literature review15–18 and a drug list from the 
EuroPE+ project,25 a questionnaire will be developed 
regarding an extensive list of possible medicines that 
European junior doctors should be able to prescribe 
safely and effectively without supervision directly after 
graduation (online supplemental appendix 2). This 
list will be categorised into diseases. For each drug, 
the most commonly used routes of administration will 
be listed separately.
Expert panel
Through the Education Working Group of the 
EACPT and the affiliated Network of Teachers in 
Pharmacotherapy, all coordinators (n=393) from all 
European medical schools (n=297) who are respon-
sible for teaching CP&T to medical students will be 
approached to participate in the study. The coordi-
nators will be asked to participate in the study them-
selves and to select a group of experts within their 
own centre, using the following criteria:
 ► Two experienced (≥3 years of teaching experience) 
teachers explicitly engaged in CP&T education for 
medical students, of which at least one teacher is 
registered as a clinical pharmacologist.
 ► At least five healthcare professionals, preferably a 
surgeon (eg, general surgeon); an internist (eg, 
general internist, gastroenterologists, pulmonologist 
and cardiologist); a general practitioner; a specialist 
in geriatric medicine or geriatrician and a (hospital)
pharmacist.
 ► Two recently graduated junior doctors (graduated 
≤1 year ago) who prescribe drugs on a daily basis.
There will be no restrictions regarding the work 
environment of the respondents (academic or 
community hospitals). The principal investigator will 
invite the experts to participate via email, providing 
an information letter and a link to the online survey. 
Prior to participation, the experts will be asked to sign 
a digital informed consent form.
Based on previous studies with this dedicated group 
of experts,22 26 we expect a response rate of 25% for 
the coordinators, representing all European coun-
tries. Assuming 5–6 recruited experts per coordinator 
and a response rate of 25% as well, we expect in total 
200–250 experts to complete the study.
Phases II and III
Study design and data collection
In phase II, the coordinator(s) of each university 
will receive the list of medicines developed in phase 
I and will be asked to indicate which medicines are 
available in his or her country. On the basis of this 
information, a second questionnaire will be drawn 
up consisting of the medicines that are available in 
Europe. This questionnaire will be used for phase III, 
a two- round Delphi study. In round 1, all experts will 
be asked to evaluate two statements for each medicine 
(item): (1) ‘In my country, it is standard practice to 
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prescribe this medicine to patients’ and (2) ‘A junior 
doctor should be able to independently prescribe this 
medicine safely and effectively without direct supervi-
sion’. Respondents will score both statements using a 
5- point Likert scale (1=strongly disagree, 2=disagree, 
3=neither agree nor disagree, 4=agree and 5=strongly 
agree). Respondents will also be able to add missing 
medicines that they consider should be included in 
round 2, and to add arguments for their choices in an 
open text box.
The questionnaire for round 2 will have the same 
structure as in round 1, but will also include the 
average group score per medicine from round 1, the 
suggested medicines and the arguments for their 
inclusion. The coordinator will be asked an additional 
question about the availability of the suggested medi-
cines in his or her country: ‘In my country, this medi-
cine is available to prescribe to patients’.
To minimise participant drop- out, the list of medi-
cines will be structured and participants are allowed 
to complete a portion of the survey and return later to 
finish the remaining part. The list must be completed 
within 2 weeks, a reminder will be send after 1 week.
Statistics
A medicine will be included in the second question-
naire if that medicine is available in ≥80% of the 
European countries. In accordance with previous 
studies,12 22 a medicine will be included in the final 
European List of Essential Medicines for Medical 
Education if both statements about this medicine 
are scored 4 or 5 by ≥80% of the respondents. If 
one statement about a medicine is scored 4 or 5 by 
≥80% of the respondents but the other statement is 
scored 4 or 5 by ≥50%–<80% of the respondents, then 
this medicine will be reassessed in Delphi round 2. 
This also applies to suggested medicines. Medicines 
from round 2 will be included in the European List 
of Essential Medicines for Medical Education if both 
statements regarding a medicine are given a score of 4 
or 5 by ≥80% of the respondents. Medicines suggested 
by respondents should also be available in ≥80% of 
European countries.
ETHICS AND DISSEMINATION
Prior to participation, all experts will be asked to give 
their informed consent and provide the following 
information: email address, medical school, profes-
sion with background, and years of clinical and 
teaching experience. The data will be coded and 
stored for a maximum of 10 years in a secure folder on 
the hard disk of the Amsterdam UMC, location VUmc. 
Participation will not be professionally advantageous 
or disadvantageous and there will be no compensa-
tion for participation. Respondents can end their 
participation at any time, without giving a reason. The 
study has been approved by the Medical Ethics Review 
Committee of Amsterdam UMC, location VUmc 
(no. 2020.335) and by the Ethical Review Board of 
the Netherlands Association for Medical Education 
(approved project no. NVMO‐ERB 2020.4.8).
The results of the study will be presented at national 
and international conferences and will be submitted 
to international peer- reviewed journals. The final 
European List of Essential Medicines for Medical 
Education will be used to develop and implement the 
European Prescribing Exam.
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